Recent studies have shown that deletion of BAFF in the NAFLD model attenuates hepatic fat accumulation, inhibits inflammation and fibrosis in VAT, improves insulin resistance, and weakens liver steatosis. The gene discussed is TNFSF13B; the disease is metabolic dysfunction-associated steatotic liver disease.